Education
About Us
Working with TipRanks
Follow Us
CytoDyn (CYDY)
OTHER OTC:CYDY
CYDY Stock Chart & Stats
$0.28
<$0.01(0.09%)
At close: 4:00 PM EST
$0.28
<$0.01(0.09%)
Day’s Range― - ―
52-Week Range$0.11 - $0.49
Previous CloseN/A
Volume1.91M
Average Volume (3M)2.14M
Market Cap
$358.59M
Enterprise Value$410.09M
Total Cash (Recent Filing)$9.33M
Total Debt (Recent Filing)$43.78M
Price to Earnings (P/E)―
Beta0.48
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,265,853,800
10 Day Avg. Volume1,933,875
30 Day Avg. Volume2,143,110
Financial Highlights & Ratios
PEG Ratio-1.05
Price to Book (P/B)-4.25
Price to Sales (P/S)-69.07
P/FCF Ratio-46.62
Enterprise Value/Market Cap1.14
Enterprise Value/Revenue-69.32
Enterprise Value/Gross Profit-24.12K
Enterprise Value/Ebitda-24.45
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CytoDyn News
CYDY FAQ
What was CytoDyn’s price range in the past 12 months?
CytoDyn lowest stock price was $0.10 and its highest was $0.49 in the past 12 months.
What is CytoDyn’s market cap?
CytoDyn’s market cap is $358.59M.
When is CytoDyn’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were CytoDyn’s earnings last quarter?
Currently, no data Available
Is CytoDyn overvalued?
According to Wall Street analysts CytoDyn’s price is currently Overvalued.
Does CytoDyn pay dividends?
CytoDyn does not currently pay dividends.
What is CytoDyn’s EPS estimate?
CytoDyn’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CytoDyn have?
CytoDyn has 1,265,853,800 shares outstanding.
What happened to CytoDyn’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of CytoDyn?
Currently, no hedge funds are holding shares in CYDY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CytoDyn Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
86.01%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-51.88%
Trailing 12-Months
Company Description
CytoDyn
CytoDyn Inc. operates as a clinical-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor in the areas of human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), oncology, and such as coronavirus disease (COVID-19). It is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
Technical Analysis
CytomX Therapeutics
―
Gossamer Bio
―
iTeos Therapeutics
―
Compass Therapeutics
―
MBX Biosciences, Inc.
―
Ownership Overview
―
Insiders
0.02% Other Institutional Investors
99.98% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---